A monoclonal antibody, an infarct-avid radiopharmaceutical labelled with Technetium 99m, directed against cardiac myosin

Concerns: Service: We are seeking partnership

- Contract Manufacturing
- Market Research & Marketing

Type:

- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Protein

Therapeutic target:

- Cardiovascular

For the following market(s):
- United States of America
- Canada

Other: Europe

Full description:

CardioVision™, one of these monoclonal antibodies, is an infarct-avid radiopharmaceutical labelled with Technetium 99m, directed against cardiac myosin (one of the contractile proteins inside the cardiac cell) and intended for the assessment of myocardial infarction, its risk stratification, the documentation of "micro-infarctions" after revascularisation procedures and thrombolysis and the monitoring of heart transplant rejection. It is produced through biotechnology by incorporating the hybridoma-cell line into a bioreactor.

Not only CardioVision™ but also its production processes are patent protected until 2009 in Canada, 2010 in Europe and 2014 in the USA. We assume that after the patent expiry the sales potential will remain unaltered due to the unique character of the hybridoma cell-line.

We are seeking partnership focusing on clinical development, production capacities and marketing experience focused on cardiology.